1. Home
  2. CYN vs PPBT Comparison

CYN vs PPBT Comparison

Compare CYN & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYN
  • PPBT
  • Stock Information
  • Founded
  • CYN 2013
  • PPBT 2010
  • Country
  • CYN United States
  • PPBT Israel
  • Employees
  • CYN N/A
  • PPBT N/A
  • Industry
  • CYN EDP Services
  • PPBT Biotechnology: Pharmaceutical Preparations
  • Sector
  • CYN Technology
  • PPBT Health Care
  • Exchange
  • CYN Nasdaq
  • PPBT Nasdaq
  • Market Cap
  • CYN 9.3M
  • PPBT 9.2M
  • IPO Year
  • CYN 2021
  • PPBT N/A
  • Fundamental
  • Price
  • CYN $6.53
  • PPBT $2.54
  • Analyst Decision
  • CYN
  • PPBT Strong Buy
  • Analyst Count
  • CYN 0
  • PPBT 2
  • Target Price
  • CYN N/A
  • PPBT $126.50
  • AVG Volume (30 Days)
  • CYN 1.8M
  • PPBT 65.5K
  • Earning Date
  • CYN 11-06-2024
  • PPBT 11-15-2024
  • Dividend Yield
  • CYN N/A
  • PPBT N/A
  • EPS Growth
  • CYN N/A
  • PPBT N/A
  • EPS
  • CYN N/A
  • PPBT N/A
  • Revenue
  • CYN $102,118.00
  • PPBT N/A
  • Revenue This Year
  • CYN $18.11
  • PPBT N/A
  • Revenue Next Year
  • CYN $418.19
  • PPBT N/A
  • P/E Ratio
  • CYN N/A
  • PPBT N/A
  • Revenue Growth
  • CYN N/A
  • PPBT N/A
  • 52 Week Low
  • CYN $2.85
  • PPBT $2.40
  • 52 Week High
  • CYN $59.50
  • PPBT $23.20
  • Technical
  • Relative Strength Index (RSI)
  • CYN 67.15
  • PPBT 31.62
  • Support Level
  • CYN $5.64
  • PPBT $2.40
  • Resistance Level
  • CYN $8.75
  • PPBT $2.80
  • Average True Range (ATR)
  • CYN 0.88
  • PPBT 0.33
  • MACD
  • CYN 0.16
  • PPBT 0.07
  • Stochastic Oscillator
  • CYN 58.43
  • PPBT 14.74

About CYN Cyngn Inc.

Cyngn Inc is an industrial autonomous vehicle technology company. Its flagship innovation is DriveMod, an autonomous driving solution that can be flexibly deployed on multiple vehicle types manufactured by Original Equipment Manufacturers in various environments.

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.

Share on Social Networks: